Understanding a drug’s mechanism of action (MOA) can greatly increase the likelihood of successful clinical trials by identifying biomarkers of patient response and providing a rationale for ...
Dave Lahr, PhD, is currently leading the computational biology group at Foghorn Therapeutics, a biotech startup focused on treating diseases by correcting abnormal gene expression. In the early days ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback